Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single‐centre experience

Abstract

Delayed recovery of thrombocytopenia is a well-known complication after alloHSCT with an incidence of 5%-37%, which may lead to life-threatening bleeding that may require treatment. [1][2][3] TRAs, romiplostim and ELT bind to the thrombopoietin, c-MPL receptors to stimulate megakaryocyte maturation and platelet production. Both drugs have been approved by the FDA, to be used in patients with primary ITP who require treatment after an initial course of corticosteroid. 4,5 Clinical evidence demonstrates that ELT

Treatment of Severe Refractory Thrombocytopenia in Brucellosis with Eltrombopag: A Case Report

“…Eltrombopag, a TPO receptor agonist, stimulates megakaryocyte proliferation and maturation. 17 adverse effects. 18 According to the American Society of Hematology 2019, in pediatric ITP with nonresponse to first-line therapy, TPO receptor agonists are preferred over rituximab and splenectomy.…”

“…Eltrombopag, a TPO receptor agonist, stimulates megakaryocyte proliferation and maturation. 17 Eltrombopag is demonstrated efficacy in raising platelet counts, reducing bleeding severity and reducing the need for concomitant ITP therapies with relatively few adverse effects. 18 According to the American Society of Hematology 2019, in pediatric ITP with nonresponse to first-line therapy, TPO receptor agonists are preferred over rituximab and splenectomy.…”

Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia

“…Eltrombopag is considered to be effective against PIT because it stimulates megakaryocyte proliferation and differentiation by activating part of the thrombopoietin signaling pathway through specific interactions with the thrombopoietin receptor. There have been some reports on the therapeutic outcomes of eltrombopag use in children with PIT, and many of them support the efficacy and relative safety of eltrombopag [ 14 , 15 , 16 ]. In our patient, administration of eltrombopag led to a recovery in platelet counts.…”

Treatment of Severe Refractory Thrombocytopenia in Brucellosis With Eltrombopag

“…Eltrombopag, a thrombopoietin receptor agonist, stimulates megakaryocyte proliferation and maturation [19]. Eltrombopag license for chronic immune thrombocytopenia (ITP) treatment in both pediatric and adult patients when the rst-line therapy or splenectomy fail [20].…”